research A phase 2a trial of brepocitinib for cicatricial alopecia
Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
Search
forResearch
5 / 1000+ results
research Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
STS01 1% effectively promotes hair regrowth with minimal side effects.
research Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
research Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial
Setipiprant did not significantly improve hair growth in men with hair loss.
research Alteration of Skin Properties with Autologous Dermal Fibroblasts
Using your own skin cells can help repair aging skin and promote hair growth.
Community Join
5 / 1000+ resultscommunity Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
community Pelage to present PP405 Phase 2a clinical trial full results at an upcoming medical meeting - CMO Christina Weng says
Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.
community Pelage Announces Positive Results of Phase 2a Trials for PP405
PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.
community Follicum releases some data from previous phase 2a trial
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
community Pp405 phase 2a clinical results
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
Experts
6 / 20 results- 82
Hair Transplant SurgeonDr. Fas Arshad, MD, MBChB, MRCS, DO-HNS, FRCS
Leeds, United Kingdom
- 84
Hair Transplant SurgeonDr. Fauzia Carullo, MD
Las Vegas, NV, United States
- 8
Hair Transplant SurgeonDr. Faouzi Khalfaoui
Tunis, Tunisia
- 18Hair Transplant Surgeon
Dr. Vassia Birou, MD
London, United Kingdom
- 19Hair Transplant Surgeon
Dr. Vassia Birou, MD
Cape Town, South Africa
- 29
SMP SpecialistFozia Hussain
Brampton, ON, Canada
Clinics
6 / 13 results- 25
Hair Loss TreatmentsAesthetics 2 A TFlower Mound, TX · US - 7Hair Loss TreatmentsDraelos Zoe Diana MDHigh Point, NC · US
- 23
TrichologyAdvanceDerma | Dr. Luis Fernando GonzalezBogotá · CO - 27Hair TransplantClinica Capilar Dr Luis PalmarinoBuenos Aires · AR
- 62Hair TransplantDr Lucia DodinBrison-Saint-Innocent · FR
- 28Hair TransplantHair Loss TreatmentsDr. Luis PeraltaDonostia / San Sebastián, Pais Vasco · ES